Vandetanib for the treatment of thyroid cancer

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 71-80

  Langmuir, P B ^a   Yver, A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PLACEBO; PROTEIN RET; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ACNE; APPETITE DISORDER; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; DERMATITIS; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRY SKIN; DYSPNEA; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INSOMNIA; NAUSEA; NONHUMAN; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SYNCOPE; THYROID MEDULLARY CARCINOMA; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84055207676     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.272     Document Type: Review

References (31)

1. Roman, S., Lin, R. & Sosa, J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107, 2134-2142 (2006). (Pubitemid 44665646)
2. Kloos, R.T. et al.; American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565-612 (2009).
3. Cohen, R., Buchsenschutz, B., Estrade, P., Gardet, P. & Modigliani, E. [Causes of death in patients with medullary cancer of the thyroid. GETC. Groupe d'Etude des Tumeurs à Calcitonine]. Presse Med. 25, 1819-1822 (1996). (Pubitemid 26401586)
4. Modigliani, E. et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'Étude des Tumeurs à Calcitonine. Clin. Endocrinol. (Oxf) 48, 265-273 (1998). (Pubitemid 28137636)
5. Donis-Keller, H. et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2, 851-856 (1993). (Pubitemid 23216611)
6. Hofstra, R.M. et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375-376 (1994).
7. Mulligan, L.M. et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460 (1993). (Pubitemid 23179393)
8. Eng, C. et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res. 56, 2167-2170 (1996). (Pubitemid 26119920)
9. Castellone, M.D. & Santoro, M. Dysregulated RET signaling in thyroid cancer. Endocrinol. Metab. Clin. North Am. 37, 363-74, viii (2008). (Pubitemid 351698089)
10. Eng, C. RET proto-oncogene in the development of human cancer. J. Clin. Oncol. 17, 380-393 (1999). (Pubitemid 29022417)
11. Elisei, R. et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682-687 (2008). (Pubitemid 351398539)
12. Marsh, D.J. et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin. Endocrinol. (Oxf) 44, 249-257 (1996). (Pubitemid 26063401)
13. Croyle, M. et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 68, 4183-4191 (2008).
14. Cerrato, A., De Falco, V. & Santoro, M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J. Mol. Endocrinol. 43, 143-155 (2009).
15. Gorla, L. et al. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Mol. Carcinog. 48, 220-231 (2009).
16. Rodríguez-Antona, C. et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr. Relat. Cancer 17, 7-16 (2010).
17. Barbet, J., Campion, L., Kraeber-Bodéré, F. & Chatal, J.F.; GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 6077-6084 (2005). (Pubitemid 41606528)
18. Giraudet, A.L. et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185-4190 (2007). (Pubitemid 350074730)
19. Wedge, S.R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645-4655 (2002).
20. Carlomagno, F. et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62, 7284-7290 (2002). (Pubitemid 36025251)
21. Knowles, P.P. et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 281, 33577-33587 (2006). (Pubitemid 46036738)
22. Wells, S.A. Jr et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28, 767-772 (2010).
23. Robinson, B.G., Paz-Ares, L., Krebs, A., Vasselli, J. & Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95, 2664-2671 (2010).
24. Wells, S.A. et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind Phase III trial (ZETA). Journal of Clinical Oncology 28(15s), abstr. 5503 (2010).
25. Natale, R.B. et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 1059-1066 (2011).
26. Lee, J. et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized double-blind phase III trial (ZEPHYR). J Clin Oncol 28(15s), abstr. 7525 (2010).
27. Vandetanib (ZD6474) Tablets: Oncologic Drugs Advisory Committee (ODAC) Meeting Briefing Document 〈http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235092. pdf〉 (2010).
28. Shah, N.T. et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J. Clin. Oncol. 23, 165-174 (2005). (Pubitemid 41702635)
29. Reck, M. & Gutzmer, R. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 33, 470-479 (2010).
30. Leboulleux, S. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind phase II trial. Ann. Oncol. 21(suppl. 8), viii 315 (abstr. 1008PD) (2010).
31. Weil, A. et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin. Pharmacokinet. 49, 607-618 (2010).